About
Small Molecules for Immuno-Oncology
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
1,385
By Phase
PHASE3: 1PHASE1/PHASE2: 1PHASE1: 2
By Status
COMPLETED: 2NOT_YET_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06680258Lead Sponsor
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
PHASE3Not yet recruiting
740 participants
Started: Dec 31, 2025 · Completed: Jul 31, 2030
NCT04524871Collaborator
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
PHASE1/PHASE2Recruiting
518 participants
Started: Nov 1, 2020 · Completed: Dec 31, 2026
NCT04344795Lead Sponsor
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
PHASE1Completed
89 participants
Started: May 6, 2020 · Completed: Sep 25, 2024
NCT03829436Lead Sponsor
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
PHASE1Completed
38 participants
Started: Mar 20, 2019 · Completed: Sep 7, 2022
Locations (1)
Headquarters
Brisbane, CA, United States
Map
Loading map...